{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-170114","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2023-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.713142+00:00","generated_at":"2026-06-13T21:20:39.872401+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Stoke Therapeutics stockholders elect three Class I directors, ratify KPMG, approve charter amendment","bullets":["Elected Adrian R. Krainer (23.7M for, 8.0M withheld), Garry E. Menzel (26.0M for, 5.7M withheld), Julie Anne Smith (30.3M for, 1.3M withheld) as Class I directors.","Ratified KPMG as independent auditor for FY 2023 with 35.5M for, 15.9K against, 987 abstentions.","Approved amendment to Certificate of Incorporation: 27.0M for, 4.6M against, 4.7K abstentions.","Broker non-votes of 3.8M shares recorded for director elections."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-170114","json":"https://secwatch.observer/filing/0001193125-23-170114.json","markdown":"https://secwatch.observer/filing/0001193125-23-170114.md","text":"https://secwatch.observer/filing/0001193125-23-170114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000119312523170114/0001193125-23-170114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000119312523170114/d520719d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T21:20:39.872401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13b4446d7f990bba80dde3f752b1869bacff847f","claim":"Stoke Therapeutics, Inc. shareholders approved Election of three Class I directors: Adrian R. Krainer, Ph.D., Garry E. Menzel, Ph.D. and Julie Anne Smith at the 2023-06-13 meeting.","evidence_excerpt":"Election of three Class I directors, Adrian R. Krainer, Ph.D., Garry E. Menzel, Ph.D. and Julie Anne Smith, each to serve a three-year term, which will expire at the 2026 Annual Meeting of Stockholders or until such time as their respective successors have been duly elected and qualified: Nominees Shares For Shares Withheld/Abstaining Broker Non-Votes Adrian R. Krainer, Ph.D. 23,672,988 7,986,841 3,838,508 Garry E. Menzel, Ph.D. 25,992,037 5,667,792 3,838,508 Julie Anne Smith 30,318,661 1,341,168 3,838,508","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1623526/000119312523170114/0001193125-23-170114-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"},{"claim_id":"b06f7e1407015bb8be7eda45910f7c7ccab8b6ad","claim":"Stoke Therapeutics, Inc. shareholders approved Approval of an amendment to the Company’s Certificate of Incorporation at the 2023-06-13 meeting.","evidence_excerpt":"Approval of an amendment to the Company’s Certificate of Incorporation: Shares For Shares Against Shares Withheld/Abstaining 27,025,612 4,629,558 4,659","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1623526/000119312523170114/0001193125-23-170114-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"},{"claim_id":"bf13fd092b7f8fd2c9bb21279fded5f8c86f9422","claim":"Stoke Therapeutics, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-13 meeting.","evidence_excerpt":"Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: Shares For Shares Against Shares Withheld/Abstaining 35,481,487 15,863 987","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1623526/000119312523170114/0001193125-23-170114-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}